Details:
Under the terms of the agreement, Inceptua will have exclusive rights to distribute and commercialize Apealea in Europe. These rights do not extend to the Nordic countries (Denmark, Finland, Norway, Sweden, Iceland).
Lead Product(s): Paclitaxel
Therapeutic Area: Oncology Product Name: Apealea
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Elevar Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 28, 2020